Pranav PatelAhmed Abd El WahedOumar FayePauline PrügerMarco KaiserSasikanya ThaloengsokSukathida UbolAnavaj SakuntabhaiIsabelle Leparc-GoffartFrank T. HufertAmadou A. SallManfred WeidmannMatthias NiedrigRobert Koch InstitutUniversität GöttingenInstitut Pasteur de DakarGenExpress GmbHMahidol UniversityInstitut Pasteur, ParisInstitute for Biomedical Research of the French Armed Forces (IRBA)Brandenburg Medical SchoolUniversity of Stirling2018-12-112019-03-142018-12-112019-03-142016-09-29PLoS Neglected Tropical Diseases. Vol.10, No.9 (2016)19352735193527272-s2.0-84992089262https://repository.li.mahidol.ac.th/handle/20.500.14594/41127© 2016 Patel et al. Background: Chikungunya virus (CHIKV) is a mosquito-borne virus currently transmitted in about 60 countries. CHIKV causes acute flu-like symptoms and in many cases prolonged musculoskeletal and joint pain. Detection of the infection is mostly done using RT-RCR or ELISA, which are not suitable for point-of-care diagnosis. Methodology/Principal Findings: In this study, a reverse transcription recombinase polymerase amplification (RT-RPA) assay for the detection of the CHIKV was developed. The assay sensitivity, specificity, and cross-reactivity were tested. CHIKV RT-RPA assay detected down to 80 genome copies/reaction in a maximum of 15 minutes. It successfully identified 18 isolates representing the three CHIKV genotypes. No cross-reactivity was detected to other alphaviruses and arboviruses except O'nyong'nyong virus, which could be differentiated by a modified RPA primer pair. Seventy-eight samples were screened both by RT-RPA and real-time RT-PCR. The diagnostic sensitivity and specificity of the CHIKV RT-RPA assay were determined at 100%. Conclusions/Significance: The developed RT-RPA assay represents a promising method for the molecular detection of CHIKV at point of need.Mahidol UniversityMedicineArticleSCOPUS10.1371/journal.pntd.0004953